Last edition
News about "novel ex vivo engineered cell therapies"
Vertex Pharma, Arbor enter new collaboration to develop novel ex vivo engineered cell therapies
Vertex Pharmaceuticals Incorporated, a global biotechnology company, and Arbor Biotechnologies (Arbor), an early-stage life sciences company, announced a new collaboration to enhance efforts in developing ex vivo engineered cell therapies, using Arbor's proprietary CRISPR gene-editing technology for select diseases
Novel Ex Vivo Engineered Cell Therapies | 25/08/2021 | By Darshana | 320
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy